ReviewCurrent cardiology reports2022
SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes.
Review in Current cardiology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- A systematic review and meta-analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D).Diabetic medicine : a journal of the British Diabetic Association · 2026 · on this mapPooled it
- Divergent Renal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Nondiabetic Kidney Disease.Kidney & blood pressure research · 2026Pooled it
- Effect of Hypoglycemic Drugs on Patients with Heart Failure with or without T2DM: A Bayesian Network Meta-analysis.Reviews in cardiovascular medicine · 2025Pooled it
- Review
- Review
- Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety.Frontiers in medicine · 2025Review
- Impact of Prescribing Patterns Before and After Short-Term, Pharmacist-Led Type 2 Diabetes Service in an Endocrinology Clinic.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Ultrasound combined with microbubble enhanced renoprotective effects of NLRP3 inflammasome inhibitor MCC950 in CKD model.Frontiers in pharmacology · 2025Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewOver the past few decades, multiple glucose lowering therapies have been developed, but until now, no single drug has proven to both decrease cardiovascular mortality and improve renal outcomes. The purpose of this review is to outline the key findings of the recent major outcome clinical trials on SGLT2 inhibitors, review the indications for their use, and improve adoption of these medications in patients with type 2 diabetes mellitus (T2DM). RECENT
findingsRecent studies have shown a benefit for SGLT2 inhibitors in patients with heart failure (HF) and kidney disease both in the presence and absence of T2DM. Additional benefits also include improvements in fluid status, blood pressure, serum uric acid levels, and weight loss. Available data suggests that SGLT2 inhibitors should be used in all eligible patients with HFrEF and/or CKD with albuminuria to decrease progression of CKD, hospitalizations for heart failure, major atherosclerotic cardiovascular events, and cardiovascular death, with and without T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.